Martingale Asset Management
AXSM icon

Martingale Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Martingale Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.16M Sell
11,709
-800
-6% -$174K 0.05% 358
2026
Q2 		$3.06M Sell
12,509
-3
-0% -$651 0.07% 292
2026
Q1 		$2.11M Buy
12,512
+5,106
+69% +$882K 0.05% 339
2025
Q4 		$1.35M Buy
7,406
+3,606
+95% +$503K 0.03% 406
2025
Q3 		$462K Sell
3,800
-1
-0% -$113 0.01% 625
2025
Q2 		$397K Buy
+3,801
New +$402K 0.01% 652

Other funds holding AXSM

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Alethea Capital Management
Alethea Capital Management Mercer Island, Washington $197M AUM 51.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Martingale Asset Management's AXSM Position: Q3 2026 in Review

Martingale Asset Management reduced its Axsome Therapeutics (AXSM) stake by 6.4% in Q3 2026, selling an estimated $174K and leaving 11,709 shares worth $2.16M. The position accounts for 0.05% of the portfolio, ranked #358.

Martingale Asset Management first reported a position in AXSM in Q2 2025 and has held it in 6 quarters since. The position peaked at $3.06M in Q2 2026. 322 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Martingale Asset Management held 11,709 shares of Axsome Therapeutics worth $2.16M as of Q3 2026.
  • Martingale Asset Management sold 800 Axsome Therapeutics shares in Q3 2026, an estimated $174K.
  • Axsome Therapeutics made up 0.05% of Martingale Asset Management's portfolio in Q3 2026, its #358 holding.
  • Martingale Asset Management first reported a position in Axsome Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Martingale Asset Management's Axsome Therapeutics position peaked at $3.06M in Q2 2026.
  • 322 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Martingale Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.